Company Filing History:
1 out of 1 
1 out of 34 Years Active: 2023
Title: Hsin-Pai Li: Innovator in Cancer Treatment Evaluation
Introduction
Hsin-Pai Li is a notable inventor based in Taoyuan, Taiwan. He has made significant contributions to the field of cancer treatment through his innovative patent. His work focuses on evaluating the suitability of individuals with cancer for treatment with CDK inhibitors.
Latest Patents
Hsin-Pai Li holds a patent titled "Method for evaluating whether an individual with cancer is suitable for treatment with a CDK inhibitor." This patent outlines a method that includes several steps: detecting the copy number of a first gene and a second gene from an in vitro sample of the individual with cancer, calculating a copy number variation ratio between these genes, and determining the suitability of the individual for CDK inhibitor administration based on the CNV ratio. This innovative approach aims to enhance the effectiveness of anti-cancer drugs.
Career Highlights
Throughout his career, Hsin-Pai Li has worked with reputable institutions, including Chang Gung Memorial Hospital in Linkou. His experience in these organizations has contributed to his expertise in cancer research and treatment methodologies.
Collaborations
Hsin-Pai Li has collaborated with Cheng-Lung Hsu, a talented woman in the field. Their partnership has likely fostered advancements in cancer treatment evaluation.
Conclusion
Hsin-Pai Li's contributions to cancer treatment evaluation through his innovative patent demonstrate his commitment to improving patient outcomes. His work is a testament to the importance of research and innovation in the medical field.